Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer

Novel therapies are urgently needed for ovarian cancer, the deadliest gynecologic malignancy. Ovarian cancer has thus far been refractory to immunotherapies that stimulate the host immune system to recognize and kill cancer cells. This may be because of a suppressive tumor immune microenvironment an...

Descripción completa

Detalles Bibliográficos
Autores principales: Moufarrij, Sara, Srivastava, Aneil, Gomez, Stephanie, Hadley, Melissa, Palmer, Erica, Austin, Paul Tran, Chisholm, Sarah, Diab, Noor, Roche, Kyle, Yu, Angela, Li, Jing, Zhu, Wenge, Lopez-Acevedo, Micael, Villagra, Alejandro, Chiappinelli, Katherine B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044433/
https://www.ncbi.nlm.nih.gov/pubmed/32103105
http://dx.doi.org/10.1038/s41598-020-60409-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044433/
https://www.ncbi.nlm.nih.gov/pubmed/32103105
http://dx.doi.org/10.1038/s41598-020-60409-4

Ejemplares similares